PATH welcomes three new Board members
Elie Alam, Keith Ashton, and Bart Cornelissen have joined PATH’s Board of Directors.
“We are pleased to welcome these three distinguished leaders to the board,” said Beth Galetti, Chair of PATH’s Board of Directors. “As we implement PATH Strategy 2030, their insight and expertise will help us advance PATH’s work of connecting innovation, evidence, financing, and delivery so that more people can access the health solutions they need.”
The new Board members bring expertise in biomedical engineering, artificial intelligence (AI), strategic finance, and business development. Read more about each new board member below:
Elie Alam
Elie Alam is a technology entrepreneur and executive with over 30 years of international experience in enterprise software, artificial intelligence, digital and business transformation. Elie is the Founder and CEO of ZANARA AI, a technology consulting firm focused on applying artificial intelligence systems to enterprise software to solve complex business challenges and improve human experiences. His career includes senior leadership positions at some of the world's leading enterprise technology companies, including Workday, SAP, and Deloitte. He has also advised early-stage AI companies on technology strategy, innovation, and growth.
Keith Ashton
Keith Ashton is a Partner, Portfolio Manager and Co-Head of Alternative Credit in the Ares Credit Group, serving on its Executive Committee of Alternative Credit and various Ares investment committees. Mr. Ashton co-authors In the Gaps, an award-winning and widely read market insights newsletter published by Ares. Prior to joining Ares in 2011, Mr. Ashton was a Partner at Indicus Advisors LLP, where he launched its global structured credit business in May 2007. Previously, Mr. Ashton was a Portfolio Manager and Head of Structured Credit at TIAA-CREF and helped launch TIAA's institutional asset management business.
Bart Cornelissen
Bart Cornelissen is Chief Financial Officer of Xencor, a clinical-stage biopharmaceutical company, and a strategic finance leader with more than 20 years of experience across pharmaceuticals, biotechnology, and global health. Previously, he led corporate finance at Seagen through rapid global growth, major licensing transactions, and the company’s $44 billion acquisition by Pfizer. He was finance lead for the malaria and neglected tropical disease teams at the Gates Foundation, and he later served as vice president of finance at the END Fund. Mr. Cornelissen is also an advisor to growth-stage startups, including Frontier Medicines and Discovery Biotech.